9 min listen
Tirzepatide: A New Treatment for Diabetes - Frankly Speaking Ep 285
FromPri-Med Podcasts
ratings:
Length:
11 minutes
Released:
Jul 18, 2022
Format:
Podcast episode
Description
Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-285
Overview: Join us for a closer look at tirzepatide, a first-in-class glucose-dependent insulinotropic peptide (GIP) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA). See how this novel glucose-lowering agent can help raise the bar in both HbA1c lowering and weight loss in patients with type 2 diabetes mellitus.
Episode resource links:
Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 May 17:1–11.
Guest: Alan Ehrlich MD, FAAFP
Music Credit: Richard Onorato
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-285
Overview: Join us for a closer look at tirzepatide, a first-in-class glucose-dependent insulinotropic peptide (GIP) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA). See how this novel glucose-lowering agent can help raise the bar in both HbA1c lowering and weight loss in patients with type 2 diabetes mellitus.
Episode resource links:
Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 May 17:1–11.
Guest: Alan Ehrlich MD, FAAFP
Music Credit: Richard Onorato
Released:
Jul 18, 2022
Format:
Podcast episode
Titles in the series (100)
Medical Marijuana: Weeding Fact from Fiction (FAQ): FAQ for Medical Marijuana: Weeding Fact from Fiction (Not for CME credit) Guest: Panagiota Caralis, MD, JD, FACP by Pri-Med Podcasts